Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface

被引:38
作者
Hu, HL
Shioda, T
Moriya, C
Xin, XM
Hasan, MK
Miyake, K
Shimada, T
Nagai, Y
机构
[1] UNIV TOKYO,INST MED SCI,DEPT VIROL INFECT,MINATO KU,TOKYO 108,JAPAN
[2] NIPPON MED COLL,DEPT BIOCHEM 2,BUNKYO KU,TOKYO 113,JAPAN
关键词
D O I
10.1128/JVI.70.11.7462-7470.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The envelope protein, gp120, of human immunodeficiency virus type 1 (HIV-1) is heavily glycosylated and sialylated, The heavy sialylation greatly affects the physical properties of the protein, as it resolves into a wide acidic pH range despite the basic pI value predicted for its polypeptide backbone (B. S. Stein and E. G. Engleman, J. Biol. Chem. 265:2640-26-19, 1990), However, the functional significance of the heavy sialylation remains elusive, Here, we show that desialylation of HIV-1 with neuraminidase greatly augments the initial virus-cell interaction, leading to remarkably enhanced viral replication and cytopathogenicity. This enhancement appeared to be a direct result of the removal of negatively charged sialic acids but not of the exposure of galactose residues or complement activation, Complementing these results, studies with inhibitors of mannosidase I and mannosidase II showed that the processing of HIV-1 oligosaccharides into the complex type to acquire the terminal sialic acid residues impeded the full replication capacity of the virus and that its prevention also enhanced virus replication and cytopathogenicity. Enhancement of infection by desialylation was found widely, with HIV-1 laboratory strains of different cell tropisms and primary isolates as well as HIV-2 and simian immunodeficiency virus, Thus, the sialylation catalyzed by host cell pathways appeared to reduce the infectivity of human and nonhuman primate lentiviruses, Our results Further suggested that desialylation would help increase the titers of HIV-based vectors.
引用
收藏
页码:7462 / 7470
页数:9
相关论文
共 35 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]   AN N-GLYCAN WITHIN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 V3 LOOP AFFECTS VIRUS NEUTRALIZATION [J].
BACK, NKT ;
SMIT, L ;
DEJONG, JJ ;
KEULEN, W ;
SCHUTTEN, M ;
GOUDSMIT, J ;
TERSMETTE, M .
VIROLOGY, 1994, 199 (02) :431-438
[3]   EFFECT OF SIALIC-ACID REMOVAL ON THE ANTIBODY-RESPONSE TO THE 3RD VARIABLE DOMAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN [J].
BENJOUAD, A ;
MABROUK, K ;
GLUCKMAN, JC ;
FENOUILLET, E .
FEBS LETTERS, 1994, 341 (2-3) :244-250
[4]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN IS MODIFIED BY O-LINKED OLIGOSACCHARIDES [J].
BERNSTEIN, HB ;
TUCKER, SP ;
HUNTER, E ;
SCHUTZBACH, JS ;
COMPANS, RW .
JOURNAL OF VIROLOGY, 1994, 68 (01) :463-468
[5]   T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS [J].
CALLEBAUT, C ;
KRUST, B ;
JACOTOT, E ;
HOVANESSIAN, AG .
SCIENCE, 1993, 262 (5142) :2045-2050
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS WITH INCREASED REPLICATIVE CAPACITY DEVELOP DURING THE ASYMPTOMATIC STAGE BEFORE DISEASE PROGRESSION [J].
CONNOR, RI ;
HO, DD .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4400-4408
[7]   BACTERIAL SIALIDASES - ROLES IN PATHOGENICITY AND NUTRITION [J].
CORFIELD, T .
GLYCOBIOLOGY, 1992, 2 (06) :509-521
[8]   INDUCTION OF HIV-1 ENVELOPE (GP120)-SPECIFIC CYTOTOXIC T-LYMPHOCYTE RESPONSES IN MICE BY RECOMBINANT CHO CELL-DERIVED GP120 IS ENHANCED BY ENZYMATIC REMOVAL OF N-LINKED GLYCANS [J].
DOE, B ;
STEIMER, KS ;
WALKER, CM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (10) :2369-2376
[9]   A HUMAN-SERUM MANNOSE-BINDING PROTEIN INHIBITS INVITRO INFECTION BY THE HUMAN IMMUNODEFICIENCY VIRUS [J].
EZEKOWITZ, RAB ;
KUHLMAN, M ;
GROOPMAN, JE ;
BYRN, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (01) :185-196
[10]  
FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17